Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India

Adeno-associated virus (AAV) vector-based gene therapy offers a new treatment option for individuals with hemophilia. Pre-existing anti-AAV antibodies significantly impact the use of AAV vectors. Even relatively low titers of AAV neutralizing antibodies (NAb) from natural AAV infections against the capsid have been shown to inhibit the transduction of intravenously administered AAV in animal models and were associated with limited efficacy in human trials. This is important for determining the primary eligibility of patients for AAV vector-based gene therapy clinical trials. Current techniques to screen AAV antibodies include AAV capsid enzyme-linked immunosorbent assay (ELISA) for total antibodies and a transduction inhibition assay (TIA) for NAb. This study developed and screened total capsid binding anti-AAV3 antibodies by using ELISA and determined NAb levels by TIA using mCherry flow cytometry in healthy individuals with hemophilia B in India. One hundred and forty-three apparently healthy controls and 92 individuals with hemophilia B were screened. The prevalence of total and NAb in healthy controls was 79.7% and 65%, respectively; the prevalence of total and NAb in patients with hemophilia B for AAV3 was 92.4% and 91.3%, respectively.

• Publication year

  2020

• Venue

  Human Gene Therapy

• Publication date

  2020-11-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/hum.2020.258PMID 33207962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

  2020cited by this paper
• Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B

  2020cited by this paper
• Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity

  2019cited by this paper
• Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays

  2019cited by this paper
• Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors

  2019cited by this paper
• Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction

  2018cited by this paper
• Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.

  2018cited by this paper
• Strategy to detect pre-existing immunity to AAV gene therapy

  2017cited by this paper
• Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration

  2016cited by this paper
• In vivo tissue-tropism of adeno-associated viral vectors.

  2016cited by this paper
• Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.

  2015cited by this paper
• Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System

  2015cited by this paper
• Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors

  2014cited by this paper
• AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy

  2014cited by this paper
• The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individuals

  2014cited by this paper
• Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy

  2013cited by this paper
• Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

  2012cited by this paper
• AAV capsid structure and cell interactions.

  2011cited by this paper
• Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

  2010cited by this paper
• Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

  2009cited by this paper
• Diverse IgG subclass responses to adeno‐associated virus infection and vector administration

  2009cited by this paper
• Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors

  2006cited by this paper
• Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.

  2004cited by this paper
• Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1

  2003cited by this paper
• Immune responses to adenovirus and adeno-associated virus in humans

  1999cited by this paper
• Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV)

  1999cited by this paper
• Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3.

  1996cited by this paper
• Electron microscopy of adenovirus-associated virus (AAV) in cell cultures.

  1966cited by this paper

• Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India

  2025cites this paper
• Understanding AAV vector immunogenicity: from particle to patient

  2024cites this paper
• Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors

  2024cites this paper
• The translational gap for gene therapies in low- and middle-income countries

  2024cites this paper
• 血友病遺伝子治療の現況

  2024cites this paper
• Recent developments in gene therapy research in India

  2024cites this paper
• Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure—ANVIAS Study

  2023cites this paper
• Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

  2023cites this paper
• Characterization of a Bioengineered AAV3B Capsid Variant with Enhanced Hepatocyte Tropism and Immune Evasion

  2023cites this paper
• Age‐stratified adeno‐associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India

  2022cites this paper
• Rational engineering of adeno‐associated virus capsid enhances human hepatocyte tropism and reduces immunogenicity

  2022cites this paper
• The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

  2022cites this paper
• Haemophilia gene therapy—Update on new country initiatives

  2022cites this paper
• T Cell-Mediated Immune Responses to AAV and AAV Vectors

  2021cites this paper
• Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays

  2021cites this paper
• Gene Therapy in Hemophilia: Recent Advances

  2021cites this paper